Hong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact® System and ClearRT™ Helical Fan-Beam kVCT Imaging
Accuray (NASDAQ: ARAY) announced the first cancer treatment in Asia utilizing the Radixact® System with ClearRT™ imaging at Hong Kong Sanatorium & Hospital (HKSH). This advanced technology enhances imaging quality, enabling precise targeting of tumors while minimizing damage to healthy tissue. The initial case involved a 35-year-old patient with tongue cancer. ClearRT significantly reduced imaging and registration times by 77%, allowing for improved patient throughput and treatment accuracy. Accuray continues to emphasize innovation in cancer treatment solutions to enhance patient care.
- First cancer treatment in Asia using Radixact System with ClearRT imaging.
- Significantly improved imaging quality for precise tumor targeting.
- 77% reduction in scanning time enhances patient throughput.
- Partnership with HKSH highlights commitment to advanced cancer care technology.
- None.
SUNNYVALE, Calif., July 22, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the medical care team at Hong Kong Sanatorium & Hospital (HKSH) in Hong Kong treated the first cancer patient in Asia using the Radixact® System, the next-generation TomoTherapy® platform, with ClearRT™ helical fan-beam kVCT imaging. With the installation of ClearRT the team has raised the bar for other hospitals using radiation therapy as an option in cancer care. The integrated helical imaging and radiation delivery system will enable the HKSH team to generate clear, high-fidelity images that improve their ability to see the tumor and adjacent healthy tissue, and will make it easier to provide more targeted treatments to more patients each day.
The HKSH medical care team was the first in Asia to treat patients with the Accuray proprietary Synchrony® technology on both the CyberKnife® M6™ and Radixact Systems and is now the first to use ClearRT with Radixact, which supports their commitment to providing excellence in cancer care using the most advanced technology available. The ability to significantly improve clarity in imaging was especially important to the team when treating their first patient, a 35 year-old man diagnosed with tongue cancer. The treatment region included the oral cavity and neck lymph nodes, so minimizing dose to nearby critical organs was crucial. ClearRT improved soft-tissue visualization, enabling the HKSH team to deliver a highly accurate and precise treatment.
"The HKSH team is excited to expand on the Radixact System's capabilities with the addition of the ClearRT imaging technology. The ClearRT imaging modality provides enhanced image quality and better soft-tissue visualization. With this new feature, the scanning time was reduced by
ClearRT is a novel, helical CT imaging solution that, when integrated with Synchrony Real-time Motion Synchronization and Adaptive Treatment Delivery Technology, on the Radixact System provides a powerful tool that enable medical care teams to deliver extremely accurate and precise ultra-hypofractionated treatments, especially to tumors that move during treatment. ClearRT helical kVCT images can be used within the Accuray PreciseART® automated dose trending tool for clinicians to evaluate if plan adaptation would be beneficial, enabling the most personalized patient care.
"Accuray is honored to have the opportunity to further our long-standing partnership with the HKSH team. They are forward thinking and put a priority on investing in innovative technology that will help them to provide more effective outcomes for their cancer patients," said Suzanne Winter, President of Accuray. "ClearRT on the Radixact System represents an evolution of the TomoTherapy platform that we believe will lead to meaningful improvements in the treatment of cancer for clinicians and their patients and increase the range of patients and tumors that can be treated."
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the anticipated benefits of ClearRT to clinicians and patients, the potential for ClearRT to lead to meaningful improvements in the treatment of cancer, clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on April 30, 2021, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Accuray
Beth Kaplan
+1 (408) 789-4426
bkaplan@accuray.com
Christy Maginn
Havas
+1 (703) 297-7194
christina.maginn@havas.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hong-kong-sanatorium--hospital-transforms-cancer-care-in-asia-with-treatment-of-first-patient-using-the-accuray-radixact-system-and-clearrt-helical-fan-beam-kvct-imaging-301338849.html
SOURCE Accuray Incorporated
FAQ
What is the significance of Accuray's treatment at Hong Kong Sanatorium & Hospital?
How does ClearRT technology benefit cancer treatment?
Who was the first patient treated with the Radixact System in Asia?
What company is behind the Radixact System?
What improvements does the Radixact System offer in cancer treatment?
